A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies
The results demonstrate the feasibility of using rBA.5 ZsG-Nluc to track viral infections and identify prophylactics and therapeutics against recent SARS-CoV-2 VoCs in vitro, ex vivo, and in vivo.